scholarly journals APOA1 Gene

2020 ◽  
Author(s):  
Keyword(s):  
Apoa1 Gene

P3-248: Association study of the APOA1 gene in an Italian population with Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T593-T593
Author(s):  
Antonio Orlacchio ◽  
Carla Babalini ◽  
Marialaura Varlese ◽  
Clarice Patrono ◽  
Antonella Borreca ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Association Study ◽  
Italian Population ◽  
Apoa1 Gene

Kaempferol ameliorates symptoms of metabolic syndrome by improving blood lipid profile and glucose tolerance

2021 ◽  
Author(s):  
Ayasa Ochiai ◽  
Mahmoud Ben Othman ◽  
Kazuichi Sakamoto
Keyword(s):  
Metabolic Syndrome ◽  
Glucose Tolerance ◽  
Molecular Mechanisms ◽  
Ldl Receptor ◽  
Blood Lipid ◽  
Apolipoprotein A1 ◽  
High Density Lipoproteins ◽  
Blood Lipid Profile ◽  
Beneficial Effects ◽  
Apoa1 Gene

Abstract Kaempferol (KPF) is a dietary polyphenol reported to have various beneficial effects on human health. However, its molecular mechanisms in regulating lipid and glucose metabolism are not fully understood. This study examined the effects of KPF on obesity, dyslipidemia, and diabetes in Tsumura, Suzuki, Obese Diabetes (TSOD) mice. The six-week administration of KPF decreased fat weight, serum total cholesterol, and low-density lipoproteins (LDLs); increased high-density lipoproteins (HDLs); and improved glucose tolerance. Additionally, KPF increased LDL receptor (LDLR) and apolipoprotein A1 (ApoA1) gene expression and decreased serum resistin levels. These findings suggest that the decrease in LDL and the increase in HDL caused by KPF may be due to increases in hepatic LDLR and ApoA1 expression, respectively. Furthermore, it is possible that the improvement in glucose tolerance by KPF may occur via resistin reduction. These mechanisms may be parts of complex mechanism by which KPF improves metabolic syndrome.

Lipid Profile of Plasma in Young Women Depending on Their Physical Activity and Hereditary Predisposition

2021 ◽  
pp. 5-15
Author(s):  
Alʼbina Z. Dautova ◽  
◽  
Valentina G. Shamratova ◽  
Elena V. Vorobʼeva ◽  
Keyword(s):  
Blood Lipids ◽  
Female Athletes ◽  
Apolipoprotein A1 ◽  
Atherogenic Index ◽  
Polymorphic Variant ◽  
Blood Levels ◽  
Peroxisome Proliferator ◽  
Peroxisome Proliferator Activated Receptor ◽  
Apoa1 Gene ◽  
Lpl Gene

We studied the association of the polymorphic rs320 variant of the lipoprotein lipase (LPL) gene, rs2016520 variant of the peroxisome proliferator-activated receptor delta (PPARD) gene and rs670 variant of the apolipoprotein A1 (APOA1) gene with blood lipids in female athletes and women not involved in sports. Key indicators of the lipid spectrum – total cholesterol (TC), triglycerides (TG), highdensity lipoproteins (HDL) and low-density lipoproteins (LDL) in the blood serum – were determined by the enzymatic method using Cormay reagents (Germany) and Fluorat-02-ABLF-T analyser (Russia). Genotyping of the samples was carried out by means of the PCR-RFLP analysis. A direct correlation was found between the *H+ allele of the rs320 polymorphic variant of the LPL gene and the blood levels of TC (r = 0.17; p = 0.01), TG (r = 0.33; p = 0.000005), LDL (r = 0.16; p = 0.02), and atherogenic index (AI) (r = 0.28; p = 0.0002), as well as an inverse correlation between this allele and HDL (r = –0.19; p = 0.009) in women not involved in sports. The *A allele of the polymorphic variant rs670 of the APOA1 gene in this group showed a negative correlation with TC (r = –0.22; p = 0.004) and TG (r = –0.31; p = 0.00004), while the polymorphic variant rs2016520 of the PPARD gene revealed a linear correlation of the *C allele with LDL (r = 0.15; p = 0.02) and AI (r = 0.16; p = 0.01). Three alleles – *H of the LPL gene, *G of the APOA1 gene and *T of the PPARD gene – demonstrated an additive effect on the decrease in TG, LDL and AI and on the increase in HDL in women regardless of their level of motor activity. There were no statistically significant differences in the level of blood lipids in female athletes with different genotypes of the LPL, PPARD, and APOA1 genes. Further research is needed involving larger samples of athletes.

Effects of сramizol on expression of the ApoA1 gene in rats with experimental hyperlipidemia

2019 ◽  
Vol 65 (5) ◽  
pp. 403-406
Author(s):  
A.V. Lizunov ◽  
I.V. Okunevich ◽  
S.V. Orlov ◽  
A.A. Lebedev ◽  
E.R. Bychkov ◽  
...  
Keyword(s):  
Normal Values ◽  
Atherogenic Index ◽  
Lipid Lowering ◽  
Blood Levels ◽  
Hypolipidemic Agents ◽  
Apoa1 Gene ◽  
Lipid Lowering Drug ◽  
Experimental Hyperlipidemia ◽  
Triton Wr 1339 ◽  
Lowering Drug

An imidazole derivative cramizol, has lipid-lowering and anti-atherogenic effects. Cramizol reduces blood levels of cholesterol and triglycerides, and also reduces the atherogenic index in animals with acute hyperlipidemia induced by Triton WR-1339. Cramizol and the lipid-lowering drug fenofibrate exhibited similar effectiveness as hypolipidemic agents. Cramizol also restores the expression of the Apoa1 gene in rats with experimentally induced hyperlipidemia to normal values. This may be a basis of its hypolipidemic and anti-atherogenic action.

Genetic Polymorphisms in the APOA1 Gene and their Relationship with Serum HDL Cholesterol Levels

Lipids ◽  
2013 ◽  
Vol 48 (12) ◽  
pp. 1207-1216 ◽  
Author(s):  
Fatemeh Bandarian ◽  
Mehdi Hedayati ◽  
Maryam Sadat Daneshpour ◽  
Mohsen Naseri ◽  
Fereidoun Azizi
Keyword(s):  
Genetic Polymorphisms ◽  
Hdl Cholesterol ◽  
Apoa1 Gene ◽  
Cholesterol Levels

Synergistic Activation of the Hydratase but Not the ApoA1 Gene by Gemfibrozil and Retinoids

1996 ◽  
Vol 804 (1 Peroxisomes) ◽  
pp. 734-735
Author(s):  
RANJAN MUKHERJEE ◽  
LILY JOW ◽  
JOSEF STRASSER ◽  
PETER SYKA ◽  
JONATHAN ROSEN ◽  
...  
Keyword(s):  
Apoa1 Gene ◽  
Synergistic Activation
Sign in / Sign up

Export Citation Format

Share Document